ArticleJAMA network open2025
Risk Factors for West Nile Neuroinvasive Disease and Mortality in the US, 2013-2024.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Decreasing the Burden of West Nile Virus Disease: The Need for More Prevention Measures.The American journal of tropical medicine and hygiene · 2026Article
- West Nile Virus in People with HIV: Immune Vulnerability, Neuroinvasive Disease, and Diagnostic Challenges.Tropical medicine and infectious disease · 2026Review
- Prevalence and characterization of West Nile virus infections among people living with HIV in Northern Italy: a sero-repository analysis.Infection · 2026Article
- Endemic progression of autochthonous West Nile virus infections in Europe.European journal of microbiology & immunology · 2026Review
- West Nile Morbidity and Mortality in a Mid-Atlantic Health Care System, 2013-2024.The American journal of tropical medicine and hygiene · 2026Article
- Spatiotemporal and Demographic Patterns of West Nile Neuroinvasive Disease in Vojvodina, Serbia, 2012-2025.Viruses · 2026Article
- Pharmaceutical Strategies for West Nile Virus in Europe, an Underrecognized Cause of Severe Disease and Mortality in Older Adults: From Supportive Care to Antiviral Development.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Article
Corrections and comments
- Update of
Authors and funding
2 authors.
Funding
Abstract
Importance: West Nile virus (WNV) is the leading mosquito-borne infection in the US, causing West Nile fever or West Nile neuroinvasive disease (WNND) with substantial morbidity and mortality. Contemporary analyses are needed to identify at-risk populations and to target interventions. Objective: To assess risk factors associated with WNND and mortality among adults with WNV infection using a national cohort from federated data. Design, Setting, and Participants: This retrospective cohort study of deidentified electronic medical record data from the TriNetX research network from January 2013 to December 2024 included patients from 65 health care organizations from across the US. Data were accessed from March 28 to April 30, 2025. Exposures: Demographic characteristics (age, sex, race, and ethnicity), comorbidities (hematologic malignant neoplasms, heart disease, diabetes, HIV infection, chronic kidney disease [CKD], liver disease, hypertension, alcohol-related disorders, cerebrovascular disease [CEVD], chronic obstructive pulmonary disease, asthma, multiple sclerosis, dementia, rheumatoid arthritis, and organ transplant), and medications (immune suppressants, antineoplastics). Main Outcomes and Measures: Primary outcomes were WNND development and all-cause mortality (at 30 days, 90 days, and overall). Results: Among the initial cohort of 3064 patients with a diagnosis of WNV infection (per the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes), those with demographic data included 1249 (53%) who were consistent with West Nile fever (624 females [50%]; mean [SD] age, 55 [17] years) and 1127 (47%) who were consistent with WNND (691 males [61%]; mean [SD] age, 59 [17] years). Risk factors associated with WNND included age (adjusted hazard ratio [AHR], 1.10 [95% CI, 1.06-1.15] per decade), male sex (AHR, 1.29 [95% CI, 1.15-1.45]), CKD (AHR, 1.21 [95% CI, 1.00-1.45]), CEVD (AHR, 1.22 [95% CI, 1.03-1.45]), hematologic malignant neoplasms (AHR, 1.38 [95% CI, 1.09-1.76]), immune suppressant use (AHR, 1.43 [95% CI, 1.11-1.83]), hypertension (AHR, 1.18 [95% CI, 1.04-1.34]), alcohol-related disorders (AHR, 1.54 [95% CI, 1.20-1.97]), and multiple sclerosis (AHR, 2.34 [95% CI, 1.62-3.37]). Significant risk factors associated with mortality were WNND (AHR, 2.49 [95% CI, 1.37-4.52] for 30-day mortality), age (AHR, 1.32 [95% CI, 1.07-1.60] per decade), CKD (AHR, 2.08 [95% CI, 1.01-3.93]), and CEVD (AHR, 2.00 [95% CI, 1.14-3.50]). Conclusions and Relevance: In this cohort study of patients with WNV infection, multiple comorbidities were identified as risk factors associated with WNND; and patients who developed WNND had increased mortality risk. Targeted prevention strategies and countermeasures for high-risk individuals may substantially reduce morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.